Advanced Medical Technology AngioScore offers the innovative AngioSculpt Scoring Balloon Catheter, which provides precise plaque scoring and vessel dilatation, making it highly effective for treating both peripheral and coronary arterial diseases. This advanced technology positions the company as a leader in minimally invasive vascular interventions.

Recent Acquisition Advantage Having been acquired by Spectranetics in 2014 for $230 million, AngioScore benefits from increased resources, market reach, and integration into a broader portfolio of medical devices, which can facilitate expansion into new markets and adoption of its products.

Growing Revenue Potential With reported revenues between $10 million and $25 million, AngioScore presents a significant growth opportunity for sales teams targeting hospitals and clinics specializing in vascular procedures looking for innovative treatment options.

Market Alignment with Industry Giants Operating in a competitive landscape alongside giants like Medtronic, Boston Scientific, and Abbott, AngioScore's specialized niche in scoring balloon technology offers a compelling value proposition for healthcare providers seeking effective, minimally invasive treatment options.

Focus on Key Markets Given its proven technology and recent corporate backing, there is substantial potential to target cardiology and peripheral vascular intervention centers, especially those interested in adopting cutting-edge devices that enhance procedural precision and patient outcomes.